comparemela.com

Dirk Oehlers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)

Lonza Group AG / Key word(s): Expansion01-Jul-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Lonza to build a new large-scale, commercial drug product fill and finish facili.

Switzerland generalMartina ribar hestericovDirk oehlersPierre alain ruffieuxJean christophe hyvertHead of external communicationsLonza group ltdLonza group ag keyScience communicationsSingapore exchange securities trading limitedSwiss exchangeLonza groupAlain ruffieuxChristophe hyvertSwiss alpsGroup ltd

Adhoc: Lonza Group AG: Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)

Lonza Group AG / Key word(s): Expansion Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH) 01-Jul-2022 / 07:01 CET/CEST Release of an ad hoc announcement

Switzerland generalMartina ribar hestericovDirk oehlersPierre alain ruffieuxJean christophe hyvertHead of external communicationsLonza group ltdLonza groupSwiss exchangeScience communicationsLonza group ag keyNews serviceSingapore exchange securities trading limitedEstablish large scaleCommercial drug product fillFinish facility

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd haemalogiHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketing

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-ar.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

/PRNewswire/ HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and.

New south walesMartina ribar hestericovDirk oehlersJeetendra vaghjianiJane loweBryce carmineHead of external communicationsLonza group ltdEuropean hematology associationSwiss exchangeHaemalogix ltd contact detailsIr departmentHaemalogix ltdSingapore exchange securities trading limitedClinical development strategic marketingPrnewswire haemalogix ltd haemalogi

vimarsana © 2020. All Rights Reserved.